ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129132	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 01/21/2026 at 18:00, 7 months 20 days ago

OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
OSE Immunotherapeutics acknowledges FDA Orphan Drug Designation granted to pegrizeprument (VEL-101) for organ rejection prevention in liver transplant patients. Veloxis Pharmaceuticals to develop and commercialize the product globally

FDA Orphan Drug Designation OSE Immunotherapeutics Pegrizeprument VEL-101
BRIEF

published on 12/09/2025 at 07:35, 9 months 2 days ago

OSE Immunotherapeutics annonce son plan stratégique pour 2026-2028

Plan Stratégique Stratégie Financière Leadership Scientifique Essai Tedopi Développement Du Lusvertikimab
BRIEF

published on 12/09/2025 at 07:35, 9 months 2 days ago

OSE Immunotherapeutics' new strategic plan for 2026-2028

Strategic Plan Funding OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
BRIEF

published on 12/09/2025 at 07:35, 9 months 2 days ago

OSE Immunotherapeutics Announces Strategic Plan for 2026–2028

Strategic Plan Financial Strategy Scientific Leadership Tedopi Trial Lusvertikimab Development
BRIEF

published on 12/09/2025 at 07:35, 9 months 2 days ago

Nouveau plan stratégique d'OSE Immunotherapeutics pour 2026-2028

Financement Plan Stratégique OSE Immunotherapeutics Lusvertikimab Tedopi® Phase 3
PRESS RELEASE

published on 12/09/2025 at 07:30, 9 months 2 days ago

OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
OSE Immunotherapeutics unveils 2026–2028 strategic plan focusing on Tedopi's phase 3, rare indications for Lusvertikimab, subcutaneous formulation in UC, and maintaining scientific leadership

Strategic Plan Scientific Leadership OSE Immunotherapeutics Tedopi Phase 3 Lusvertikimab Indications
PRESS RELEASE

published on 12/09/2025 at 07:30, 9 months 2 days ago

OSE Immunotherapeutics dévoile son plan stratégique 2026 - 2028 axé sur quatre leviers de création de valeur
OSE Immunotherapeutics dévoile un plan stratégique 2026-2028 axé sur la phase 3 de Tedopi®, Lusvertikimab, et la RCH, renforçant l'engagement en immunologie

Plan Stratégique Valeur OSE Immunotherapeutics Immunologie Catalyseurs
PRESS RELEASE

published on 10/16/2025 at 19:58, 10 months 25 days ago

RAPPORT FINANCIER SEMESTRIEL 2025
BRIEF

published on 10/15/2025 at 19:05, 10 months 26 days ago

OSE Immunotherapeutics Reports 2025 First Half Financial Results

Revenue Decline OSE Immunotherapeutics Cash Runway R&D Expenses 2025 Financial Results
BRIEF

published on 10/15/2025 at 19:05, 10 months 26 days ago

OSE Immunotherapeutics publie ses résultats financiers du premier semestre 2025

Baisse Des Revenus OSE Immunotherapeutics Dépenses De R&D Piste De Trésorerie Résultats Financiers 2025

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 33 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 8 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 47 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 13 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 33 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 10:15, 1 hour 18 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours 13 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 28 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 33 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 2 hours 33 minutes ago

Picton Property Income Limited - Removal

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 33 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 33 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 33 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 33 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 16 hours 3 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE